Company News

Rifasutenizole for H. pylori Completed First Patient In of Phase III Clinical Trials in China

2023-05-22
Suzhou, China, May 20, 2023 – TenNor Therapeutics (Suzhou) Limited announced that its investigational new drug Rifasutenizole (TNP-2198) for the treatment of Helicobacter pylori infection has compl...

Rifasutenizole for H. pylori Received FDA QIDP Designation

2023-04-15
Suzhou, China, April 11, 2023 – TenNor Therapeutics (Suzhou) Limited announced that its investigational new drug Rifasutenizole (TNP-2198) for the treatment of Helicobacter pylori infection has bee...

Rifasutenizole for Helicobacter pylori Received IND Approval by the FDA

2023-03-13
Suzhou, China, March 13, 2023 – TenNor Therapeutics announced that its investigational new drug Rifasutenizole (TNP-2198) for the treatment of Helicobacter pylori infection has received IND approva...

TenNor Completed 264 million RMB Series D Financing

2022-03-30
March 30, 2022 TenNor Therapeutics (Suzhou) Limited announced the completion of 264 million RMB series D financing, led jointly by Yanchuang Capital and GTJA Investment, followed by Galaxy Capital,...

TENNOR DISCLOSES OF TNP-2198 FOR H. PYLORI INFECTIONS

2022-02-18
TenNor Discloses TNP-2198 for the Treatment of H. pylori Infections in the Journal of Medicinal Chemistry February 18, 2022 TNP-2198, a stable conjugate of a rifamycin pharmacophore and a nitr...

TenNor Reports Positive Phase II Results for TNP-2092 Capsule

2021-11-23
SUZHOU, China, Nov. 22, 2021 --TenNor Therapeutics reports positive top-line results for TNP-2092 Capsule from a phase II clinical trial for the treatment of hyperammonemia/hepatic encephalopathy i...
more
©2013 TENNOR THERAPEUTICS LTD